Personalized Medicine and Epidermal Growth Factor Receptor Mutation in Non‐Small Cell Lung Cancer: A study from National Research Institute of Tuberculosis and Lung Disease

Non-Small Cell Lung Cancer (NSCLC) comprises about 80-85% of all lung cancers. Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase and appears to play a central role in tumor genesis, and targeting this receptor may provide a unique approach for treating EGFR-expressing cancers. Successful examples of translating cancer genomics into therapeutics its potential to make possible personalized cancer medicine. 147 eligible participants were adults with NSCLC advanced disease from 2014 to 2017 whom referred to National Institute of Tuberculosis and Lung Disease (NRITLD), Masih Daneshvari Hospital. Informed written consent was obtained prior to participating patients in the study according to Shahid Beheshti Medical University’s ethics. According to presence or absence of EGFR mutation and also, patient s demand and consensus, patients were treated with tyrosine kinase inhibitors(TKIs) or other standard first-line chemotherapy. The primary endpoint was progression free survival (PFS).DNA was extracted from paraffin-embedded of each tumor block. EGFR mutation study was done by polymerase chain reaction( PCR)-based direct sequencing at a central laboratory. Results: Figure 1 shows the trial profile. From EGFR mutant group, 24 (61.7%) were female and rest of them (n=15,38.5%) were male. Most common EGFR mutation was deletion in exon 19(n=18, 46.1%) and other mutations were (n=17,43.5%) in exon 21 and in exon 18 in 2 patients(5.1%). One patient had both mutations in exon 18, and 21. In 2 patients EGFR mutation exon was not determined. Progression was observed in 14patients (35.8%). It is significant statistical difference between patients with EGFR mutation who treated by TKIs and who received other chemotherapy agents in term of disease progression (P value=0.019).Our data revealed that personalized medicine is specific and selective treatment which targets oncogensis and may control tumor growth and invasiveness.

کلیدواژه ها:

Personalized Medicine ، Epidermal Growth Factor Receptor ، Non-Small Cell Lung Cancer ، Oncogenes